Table 2.

Prior treatments.

	Glembatumumab vedotin (n = 218)		Capecitabine (n = 109)		All patients (n = 327)
	No.	%	No.	%	No.	%
No. of prior cytotoxic-containing regimens in metastatic setting
Median	1		1		1
Rangea	0–3		0–4		0–4
No. of prior relapses in the advanced setting
0	45	21	21	19	66	20
1	122	56	58	53	180	55
2	42	19	24	22	66	20
3	9	4	6	6	15	5
Prior anthracycline	185	85	95	87	280	86
Prior taxane
No. of prior taxane therapies
0	0	0	1	1	1	<1
1	164	75	74	68	238	73
2	51	23	33	30	84	26
≥3	3	1	1	1	4	1
Progression-free interval post taxaneb
≤6 months	112	51	51	47	163	50
>6 months	106	49	58	53	164	50

^aProtocol eligibility required no more than two cytotoxic regimens in the advanced setting. There was one patient in each treatment arm that did deviate from this eligibility criteria.

^bDetermined from the last taxane received.